These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31318041)

  • 61. Excellent response to tofacitinib treatment in a patient with alopecia universalis.
    Erduran F; Adışen E; Aksakal AB
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):47-49. PubMed ID: 28632888
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tofacitinib for the Treatment of Trachyonychia.
    Zhong X; Liu T; Wei L; Bai J; Fang H; Qiao J
    Am J Ther; 2024 Jul-Aug 01; 31(4):e468-e470. PubMed ID: 38976532
    [No Abstract]   [Full Text] [Related]  

  • 63. Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis.
    Kuwabara S; Tanimura S; Matsumoto S; Nakamura H; Horita T
    Ann Rheum Dis; 2020 Aug; 79(8):1125-1126. PubMed ID: 32213500
    [No Abstract]   [Full Text] [Related]  

  • 64. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
    Cheng MW; Kehl A; Worswick S; Goh C
    J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tofacitinib-induced remission in refractory adult-onset Still's disease complicated by macrophage activation syndrome.
    Honda M; Moriyama M; Kondo M; Kumakura S; Murakawa Y
    Scand J Rheumatol; 2020 Jul; 49(4):336-338. PubMed ID: 32329389
    [No Abstract]   [Full Text] [Related]  

  • 66. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre.
    You H; Zhang G; Wang Q; Zhang S; Zhao J; Tian X; Li H; Li M; Zeng X
    Ann Rheum Dis; 2019 Oct; 78(10):1441-1443. PubMed ID: 31005902
    [No Abstract]   [Full Text] [Related]  

  • 67. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.
    McKesey J; Pandya AG
    J Am Acad Dermatol; 2019 Aug; 81(2):646-648. PubMed ID: 31009664
    [No Abstract]   [Full Text] [Related]  

  • 68. Current and future oral systemic therapies for psoriasis.
    Kelly JB; Foley P; Strober BE
    Dermatol Clin; 2015 Jan; 33(1):91-109. PubMed ID: 25412786
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
    Yiu ZZ; Warren RB
    Am J Clin Dermatol; 2016 Jun; 17(3):191-200. PubMed ID: 26923915
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New systemic therapies for psoriasis.
    Mansouri Y; Goldenberg G
    Cutis; 2015 Mar; 95(3):155-60. PubMed ID: 25844781
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Successful therapy of refractory cutaneous morphea with tofacitinib.
    Russo G; Dumont S; Laffitte E
    Ital J Dermatol Venerol; 2024 Aug; 159(4):469-470. PubMed ID: 38780912
    [No Abstract]   [Full Text] [Related]  

  • 72. Tofacitinib: a successful treatment option for SAPHO syndrome.
    Sarikaya Solak S; Yelgen Ilyas H
    Int J Dermatol; 2024 May; 63(5):671-674. PubMed ID: 38357788
    [No Abstract]   [Full Text] [Related]  

  • 73. Tofacitinib Treatment for Pretibial Myxedema.
    Wang S; Chen X; Bai J; Sun Q; Fang H; Qiao J
    JAMA Dermatol; 2024 May; 160(5):578-580. PubMed ID: 38568614
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Successful treatment of rheumatoid neutrophilic panniculitis with tofacitinib.
    Almeida Junior HL; Furtado VD; Issaacson VS; Boff AL
    An Bras Dermatol; 2024; 99(4):644-647. PubMed ID: 38658238
    [No Abstract]   [Full Text] [Related]  

  • 75. Tofacitinib for treatment of rheumatoid arthritis.
    Rakieh C; Conaghan PG
    Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.
    Valenzuela F; Paul C; Mallbris L; Tan H; Papacharalambous J; Valdez H; Mamolo C
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1753-1759. PubMed ID: 27271195
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Janus kinase inhibition as a potential strategy for the treatment of psoriasis: state of the art and future perspectives.
    Cassano N; Vena GA
    J Biol Regul Homeost Agents; 2012; 26(4):587-96. PubMed ID: 23241109
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy of tofacitinib treatment in ulcerative colitis.
    Panés J; Gisbert JP
    Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tofacitinib in ulcerative colitis - In the era of precision medicine'.
    Harindranath S; Singh A
    Dig Liver Dis; 2024 May; 56(5):909-910. PubMed ID: 38310053
    [No Abstract]   [Full Text] [Related]  

  • 80. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
    Kuo CM; Tung TH; Wang SH; Chi CC
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):355-362. PubMed ID: 29136293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.